{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":45,"searchCount":0},"additional":{"submitter":["Nakamura A"],"funding":["Swiss National Science Foundation","European Research Council","Japan Agency for Medical Research and Development","Japan Society for the Promotion of Science"],"pagination":["101522"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7498753"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(9)"],"pubmed_abstract":["Asperuloside (ASP) is an iridoid glycoside that is extracted from <i>Eucommia</i> leaves. <i>Eucommia</i> is used in traditional Chinese medicine and has a long history of benefits on health and longevity. Here, we investigated the impact of ASP on obesity-related metabolic disorders and show that ASP reduces body weight gain, glucose intolerance, and insulin resistance effectively in mice fed with a high-fat diet (HFD). Intestinal dysbiosis is closely linked with metabolic disorders. Our data indicate that ASP achieves these benefits on metabolic homeostasis by reversing HFD-induced gut dysbiosis and by changing gut-derived secondary metabolites and metabolic signaling. Our results indicate that ASP may be used to regulate gut microbiota for the treatment of obesity and type 2 diabetes."],"journal":["iScience"],"pubmed_title":["Asperuloside Improves Obesity and Type 2 Diabetes through Modulation of Gut Microbiota and Metabolic Signaling."],"pmcid":["PMC7498753"],"funding_grant_id":["787702","179435"],"pubmed_authors":["Itoh H","Yokoyama Y","Benegiamo G","Fukuda S","Auwerx J","Sugizaki T","Morimoto K","Hirayama A","Nakamura A","Kitamura N","Watanabe M","Tsubota K","Tanaka K","Zhu Q"],"view_count":["45"],"additional_accession":[]},"is_claimable":false,"name":"Asperuloside Improves Obesity and Type 2 Diabetes through Modulation of Gut Microbiota and Metabolic Signaling.","description":"Asperuloside (ASP) is an iridoid glycoside that is extracted from <i>Eucommia</i> leaves. <i>Eucommia</i> is used in traditional Chinese medicine and has a long history of benefits on health and longevity. Here, we investigated the impact of ASP on obesity-related metabolic disorders and show that ASP reduces body weight gain, glucose intolerance, and insulin resistance effectively in mice fed with a high-fat diet (HFD). Intestinal dysbiosis is closely linked with metabolic disorders. Our data indicate that ASP achieves these benefits on metabolic homeostasis by reversing HFD-induced gut dysbiosis and by changing gut-derived secondary metabolites and metabolic signaling. Our results indicate that ASP may be used to regulate gut microbiota for the treatment of obesity and type 2 diabetes.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2024-11-14T01:09:59.734Z","creation":"2020-09-30T07:01:23Z"},"accession":"S-EPMC7498753","cross_references":{"pubmed":["32932138"],"doi":["10.1016/j.isci.2020.101522"]}}